iBio, Inc.
- Open
- 1.76
- Day high
- 2.11
- Day low
- 1.76
- Prev close
- 1.75
- Volume
- 3.4M
- Mkt cap
- $92M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.2
- P/S
- 305.5
- Yield
- —
- Per share
- —
iBio, Inc. (IBIO) is a Healthcare company listed on NASDAQ. The stock is up 133% over the past year.
iBio, Inc. (IBIO) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
IBIO earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 12, 2026 | $-0.06 | $-0.07 | -16.7% | — | — |
| Nov 12, 2025 | $-0.07 | $-0.11 | -57.1% | $100000 | +200.0% |
| Sep 5, 2025 | $-0.39 | $-0.31 | +20.5% | $200000 | +100.0% |
| May 2, 2025 | $-0.39 | $-0.49 | -25.6% | — | — |
| Sep 25, 2024 | $-0.47 | $-0.91 | -93.6% | $175000 | — |
| Feb 9, 2024 | — | $-2.42 | — | — | — |
| Nov 14, 2023 | — | $-4.20 | — | $50000 | — |
| May 11, 2023 | $-3.42 | $-6.61 | -93.4% | $200000 | +0.0% |
| Feb 14, 2023 | $-146.90 | $-21.60 | +85.3% | — | — |
| Nov 14, 2022 | $-1.85 | $-2.05 | -10.8% | $56000 | -90.7% |
| May 12, 2022 | $-1.25 | $-30.00 | -2300.0% | $2M | +871.5% |
| Feb 14, 2022 | $-1.00 | $-25.00 | -2400.0% | $168000 | -32.8% |
IBIO insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 19, 2026 | Stoner Elizabethdirector | Grant | 60,000 | $1.42 |
| Mar 27, 2026 | Banjak Marcofficer: Chief Legal Officer | Buy | 1,434 | $1.76 |
| Mar 27, 2026 | Banjak Marcofficer: Chief Legal Officer | Buy | 12,500 | $1.64 |
| Mar 23, 2026 | Brenner Martindirector, officer: See Remarks | Buy | 12,336 | $2.02 |
| Mar 23, 2026 | Duran Felipeofficer: Chief Financial Officer | Buy | 24,835 | $2.02 |
| Jan 30, 2026 | Brenner Martindirector, officer: See Remarks | Grant | 479,000 | $2.23 |
| Jan 30, 2026 | Duran Felipeofficer: Chief Financial Officer | Grant | 179,000 | $2.23 |
| Jan 30, 2026 | Banjak Marcofficer: Chief Legal Officer | Grant | 146,000 | $2.23 |
| Nov 24, 2025 | Sender Garydirector | Grant | 13,500 | $1.00 |
| Nov 24, 2025 | Clark William Ddirector | Grant | 13,500 | $1.00 |
| Nov 24, 2025 | Schimmelpennink Evert B.director | Grant | 13,500 | $1.00 |
| Nov 24, 2025 | Kropotova Alexandradirector | Grant | 13,500 | $1.00 |
| Nov 24, 2025 | Parada Antonio Bernardino Guimaraesdirector | Grant | 13,500 | $1.00 |
| Nov 24, 2025 | Arkowitz Daviddirector | Grant | 13,500 | $1.00 |
| Oct 22, 2025 | Duran Felipeofficer: Chief Financial Officer | Grant | 75,000 | $0.89 |
Source: IBIO SEC Form 4 filings, latest May 19, 2026. For informational purposes only — not investment advice.
See the full IBIO insider & 13F page →iBio, Inc. company profile
Overview
iBio, Inc. (NASDAQ:IBIO) is a biotechnology company founded in 2008 and headquartered in Bryan, Texas. The company operates as a contract development and manufacturing organization while simultaneously developing its own therapeutic pipeline. iBio has evolved from a plant-based manufacturing platform company into an immuno-oncology focused biotechnology firm, particularly following its 2022 acquisition of RubrYc's AI-driven drug discovery platform. The company trades on public markets and serves both internal drug development programs and external pharmaceutical clients through its specialized manufacturing and development services.
Business
iBio operates in the biotechnology sector with two primary business segments: Biopharmaceuticals and Bioprocessing. The biopharmaceuticals segment focuses on developing proprietary therapeutic candidates, while the bioprocessing segment provides contract development and manufacturing services to third-party clients. The company's core technology platform, called FastPharming, utilizes plant-based systems to produce recombinant proteins and biologics. This approach involves genetically modifying plants to produce therapeutic proteins, which can then be extracted and purified for pharmaceutical use. Plant-based manufacturing offers potential advantages including lower costs, reduced contamination risks, and scalability compared to traditional cell culture methods used in biomanufacturing. iBio's internal drug pipeline includes several therapeutic candidates in various stages of development. IBIO-100 represents the lead therapeutic candidate being developed for systemic scleroderma and idiopathic pulmonary fibrosis - serious autoimmune and fibrotic diseases affecting connective tissues and lungs respectively. The company also develops IBIO-101, an anti-CD25 antibody for immuno-oncology applications targeting cancer treatment. Additionally, iBio has vaccine candidates including IBIO-200 and IBIO-201 for COVID-19 prevention, though development priorities have shifted following limited efficacy results. The contract services business offers process development, manufacturing, filling and finishing, and bioanalytical services to pharmaceutical and biotechnology clients. This includes both catalog products and custom development work for recombinant proteins. Revenue distribution heavily favors the contract services segment, with the biopharmaceuticals segment generating minimal revenue as the internal pipeline remains in early development stages.
Revenue model
iBio generates revenue primarily through its contract development and manufacturing services, operating on a fee-for-service model where pharmaceutical and biotechnology clients pay for specific development and manufacturing work. The company charges for process development, protein production, analytical testing, and other specialized services related to biologics manufacturing. Recent financial data shows contract services revenue of approximately $200,000-$375,000 annually, representing nearly all of the company's current revenue stream. The internal biopharmaceuticals pipeline does not yet generate revenue, as all therapeutic candidates remain in preclinical or early clinical development stages. Future revenue from this segment would come through traditional pharmaceutical business models including licensing deals, milestone payments, royalties, or eventual product sales if candidates reach commercialization. Several factors significantly impact iBio's margins and profitability. Positive margin drivers include the scalability of plant-based manufacturing once established, potential cost advantages over traditional cell culture methods, and the company's AI-driven drug discovery platform acquired through RubrYc that could accelerate development timelines and reduce research costs. The FastPharming platform's ability to produce multiple products from the same infrastructure also provides operational leverage. Negative margin pressures include the high fixed costs of maintaining specialized manufacturing facilities and research capabilities, intensive regulatory requirements for biotechnology development that drive up compliance costs, and the inherent risk and expense of drug development where most candidates fail before reaching market. The company also faces competitive pressure from established contract manufacturing organizations with larger scale and broader service offerings. Additionally, iBio's current small scale limits its ability to achieve manufacturing efficiencies, while the specialized nature of plant-based production may restrict its addressable market compared to more conventional manufacturing approaches.
Competitive moat
iBio's competitive moat appears relatively limited in the current biotechnology landscape. The company's primary differentiator lies in its FastPharming plant-based manufacturing platform, which offers potential cost and safety advantages over traditional cell culture methods. However, this technology has not yet demonstrated clear superiority or widespread adoption that would create a strong defensive position. The plant-based manufacturing approach faces significant competition from well-established cell culture and microbial production systems that dominate the biologics manufacturing industry. Major contract manufacturing organizations like Lonza, Samsung Biologics, and WuXi Biologics operate at much larger scales with proven track records, making it challenging for iBio to compete on cost or reliability. Additionally, many pharmaceutical companies have developed internal manufacturing capabilities or prefer working with larger, more established partners. iBio's AI-driven drug discovery platform acquired through RubrYc provides some technological differentiation, but artificial intelligence applications in drug discovery have become increasingly common across the biotechnology industry. Companies like Recursion Pharmaceuticals, Exscientia, and numerous others are pursuing similar AI-enhanced approaches, limiting the uniqueness of this capability. The company's specialized expertise in immuno-oncology and its specific therapeutic targets may provide some competitive advantages, but these remain unproven until clinical trials demonstrate efficacy. The biotechnology sector's high failure rates mean that even promising early-stage assets carry substantial execution risk. Potential disruption could come from advances in traditional manufacturing methods that eliminate plant-based advantages, larger pharmaceutical companies developing internal plant-based capabilities, or more successful AI-driven drug discovery platforms that outperform iBio's approach. The company's small scale and limited resources also make it vulnerable to better-funded competitors who can invest more heavily in technology development and market expansion.
Risks & safety
iBio presents significant financial risk with limited margin of safety based on current metrics and cash burn trajectory. Cash and Liquidity Position: • Cash and short-term investments: $4.96 million (Q3 2025) • Quarterly cash burn: approximately $3.1-3.9 million based on operating cash flow • Current runway: approximately 4-5 quarters at current burn rate • Working capital: $663,000 (current assets minus current liabilities) Debt and Solvency: • Debt-to-equity ratio: 0.26 (relatively low debt burden) • Current ratio: 1.12 (tight liquidity position) • Total liabilities: $7.7 million versus $19.1 million in assets • No immediate solvency crisis but cash runway concerns Valuation Metrics: • Market cap: approximately $16.3 million • Price-to-book ratio: 3.48 (elevated for asset base) • Enterprise value negative due to cash position • Revenue run-rate under $1 million annually • Significant losses: $4.9 million net loss in recent quarter Other Considerations: • Pre-revenue internal pipeline with no near-term commercialization prospects • Minimal contract services revenue provides limited cash flow support • Biotech sector volatility and regulatory risks • Need for additional financing likely within 12-18 months
Recent development
iBio has undergone significant strategic transformation over the past few years, pivoting from a plant-based manufacturing platform company toward an immuno-oncology focused biotechnology firm. The most significant development was the 2022 acquisition of RubrYc's AI-driven drug discovery platform for approximately $1 million upfront in iBio stock, with potential additional milestone payments up to $5 million. This acquisition added four new pipeline assets including three immuno-oncology candidates and one PD-1 agonist for autoimmune diseases. The company has advanced its lead therapeutic candidate IBIO-101, an anti-CD25 antibody, through preclinical development and submitted a pre-IND package to the FDA. Management expects to file an Investigational New Drug (IND) application in the first half of 2024, marking a significant milestone toward potential clinical trials. This represents iBio's most advanced internal therapeutic program. iBio has also made strategic decisions to discontinue certain development programs based on efficacy data. The company's COVID-19 vaccine candidates IBIO-200 and IBIO-201 showed limited protective effects in preclinical studies, leading management to abandon IND submission plans for these programs. This decision reflects a more disciplined approach to resource allocation, focusing on programs with higher probability of success. The company has been actively exploring partnership opportunities and asset sales to extend its cash runway and advance development programs. Management has conducted comprehensive portfolio reviews and is evaluating multiple financing options including non-dilutive methods, strategic partnerships, and potential asset divestments. This reflects the challenging financial position facing many early-stage biotechnology companies. Recent quarters have shown minimal contract services revenue, with quarterly revenues ranging from zero to $200,000, indicating challenges in the commercial manufacturing business. The company continues to offer process development, manufacturing, and analytical services but has not achieved significant scale in this segment.
IBIO company profile · for informational purposes only — not investment advice.
Track IBIO with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free